2025/01/17 by Mahsa Farasat, Farasat, Mahsa, Behrad Saeedi +20
Physics and Astronomy · #Accelerator Physics (physics.acc-ph) #FOS: Physical sciences #Medical Physics (physics.med-ph) #Nuclear Experiment (nucl-ex) #Nuclear Physics and Applications #Radiation Detection and Scintillator Technologies #Radioactive Decay and Measurement Techniques
paper · pdf · doi:10.48550/arxiv.2501.10608
openalex publication_date 2025/01/17 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
Targeted alpha-particle therapy (TAT) employs alpha-emitting radionuclides conjugated to tumor-targeting molecules to deliver localized radiation to cancer cells, showing great promise in treating metastatic cancers. Among these radionuclides, Actinium-225 (225Ac, t1/2 = 9.9 days) has emerged as a clinically promising candidate. Its decay chain generates four successive alpha emissions, resulting in highly localized and effective cytotoxic damage to cancer cells when delivered to tumor sites. However, the assumption of complete retention of 225Ac and its radioactive daughters at these target sites is often inaccurate. The nuclear recoil effect can lead to off-target distribution and unintended toxicity. Our results revealed distinct spectral differences between radiolabeled cells and reference samples, demonstrating [225Ac]Ac-crown-TATE uptake by AR42J cells. Detection of 213Po, one of the 225Ac decay daughters, highlighted partial retention and release of decay products from cells, providing information on intracellular retention and daughter redistribution. Geant4 simulations confirmed the alignment of experimental data with theoretical models, validating the method's accuracy. This study establishes a direct alpha spectroscopy approach for investigating 225Ac and its daughters' behavior in cells and offers a powerful tool for microdosimetry estimation.